

Datasheet: MCA1614PE

BATCH NUMBER 1114

Description:	MOUSE ANTI HUMAN CD55:RPE
Specificity:	CD55
Other names:	DAF
Format:	RPE
Product Type:	Monoclonal Antibody
Clone:	67
Isotype:	IgG1
Quantity:	100 TESTS

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/2

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Product Form	Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized		
Reconstitution	Reconstitute with 1 ml distilled water		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	RPE 488nm laser	496	578
Preparation	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant		
Buffer Solution	Phosphate buffered saline		
Preservative	0.09% Sodium Azide		
Stabilisers	1% Bovine Serum Albumin		

5% Sucrose

Immunogen	K562 cells
------------------	------------

External Database Links	UniProt: P08174 Related reagents
	Entrez Gene: 1604 CD55 Related reagents

Synonyms	CR, DAF
-----------------	---------

RRID	AB_321500
-------------	-----------

Specificity	<p>Mouse anti Human CD55 antibody, clone 67 recognizes the human CD55 cell surface antigen, a GPI linked molecule also known as decay accelerating factor (DAF). CD55 is expressed by a wide range of cell types.</p> <p>CD55 is the complement regulatory protein, decay accelerating factor (DAF) (Lublin and Atkinson 1989). Human CD55 is a ~70 kDa glycoprotein (in erythrocytes) anchored in the membrane by glycosylphosphatidylinositol tail. In other cells the apparent molecular weight is somewhat larger. It has a substantial content of O-glycans, and also on N-glycan. DAF binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways. DAF carries the Cromer related blood group antigens.</p> <p>DAF has a wide distribution on cells in non-haematopoietic tissues, particularly epithelium and is found at the fetal-maternal interface in placenta (Holmes et al. 1990 and Yang et al. 2009). Soluble forms of DAF are found, for example, in plasma, saliva and urine (Medof et al. 1987). The antigen on erythrocytes is pronase and chymotrypsin sensitive, but resistant to trypsin.</p>
--------------------	--

Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells in 100ul.
-----------------------	---

References	<ol style="list-style-type: none">1. Hadam, M.R. (1989) In Leucocyte Typing IV: White Cell Differentiation Antigens. Edited by Knapp, W. <i>et al.</i> Oxford University Press pp 694-697.2. Holmes, C.H. <i>et al.</i> (1990) Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol. 144 (8): 3099-105.3. O'Brien, D.P. <i>et al.</i> (2009) Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor. J Biol Chem. 283: 23922-30.4. Yang, P. <i>et al.</i> (2009) Expression and modulation of RPE cell membrane complement regulatory proteins. Invest Ophthalmol Vis Sci. 50: 3473-81.5. van de Sande, M.G. <i>et al.</i> (2011) Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 70: 772-7.6. Mo, B. <i>et al.</i> (2006) ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod. 75: 387-94.
-------------------	---

7. Araten, D.J. *et al.* (2005) A quantitative measurement of the human somatic mutation rate. [Cancer Res. 65: 8111-7.](#)
8. de Launay, D. *et al.* (2010) Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis. [Am J Pathol. 177: 3010-24.](#)
9. Gheorghe, K.R. *et al.* (2011) Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression. [PLoS One. ;6: e16378.](#)
10. Kraan, M.C. *et al.* (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. [Ann Rheum Dis. 63: 483-8.](#)
11. van Holten, J. *et al.* (2005) A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. [Ann Rheum Dis. 64 \(1\): 64-9.](#)
12. Abreu, J.R. *et al.* (2009) The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue. [Arthritis Res Ther.11\(4\):R121.](#)
13. Thurlings, R.M. *et al.* (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. [Ann Rheum Dis. 67 \(7\): 917-25.](#)
14. Vos, K. *et al.* (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. [Arthritis Rheum. 56 \(3\): 772-8.](#)
15. Edginton S *et al.* (2016) Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium. [J Rheumatol. 43 \(5\): 846-54.](#)

Further Reading

1. Lublin, D.M. & Atkinson, J.P. (1989) Decay-accelerating factor: biochemistry, molecular biology, and function. [Annu Rev Immunol. 7: 35-58.](#)
2. Daniels, G. (1989) Cromer-related antigens--blood group determinants on decay-accelerating factor. [Vox Sang. 56 \(4\): 205-11.](#)

Storage

Prior to reconstitution store at +4°C. Following reconstitution store at +4°C.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

12 months from date of despatch

Health And Safety Information

Material Safety Datasheet documentation #20487 available at: <https://www.bio-rad-antibodies.com/SDS/MCA1614PE>
20487

Regulatory

For research purposes only

Related Products

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:RPE \(MCA928PE\)](#)

Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M375346:210104'

Printed on 19 Jan 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)